An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

开始日期2024-04-30

申办/合作机构

Alexion Pharmaceuticals, Inc.

ACTRN12624000307505 / Not yet recruitingN/A

Does continuing folic acid supplementation after the first trimester alter the risk of gestational diabetes mellitus: a randomised controlled trial.

开始日期2024-04-01

申办/合作机构

South Australian Health & Medical Research Institute Ltd.

NCT06349616 / Not yet recruitingN/AIIT

Acute and Chronic Interventions to Improve Heat Loss During Uncompensable Humid Heat Stress in Older Adults

The earth's climate is warming, and the number of heat waves has increased in recent years. At the same time, the number of adults over the age of 65 is growing. Humans sweat and increase blood flow to the skin to cool their body when they get hot. Older adults do not do this as well as young adults. This makes it harder to safely be in warm and/or humid conditions. It is important to learn about cooling strategies for older adults to safely be in warm and/or humid conditions.
There is compelling evidence that intermittent hand and forearm cold-water immersion effectively reduces the rise of core temperature during heat stress in older adults. However, it is still unknown if this is an effective cooling strategy for older adults. Furthermore, our laboratory has shown that folic acid supplementation improves blood flow responses in older adults. This may be beneficial to older adults during heat stress.

开始日期2024-04-01

申办/合作机构

The Pennsylvania State University

100 项与叶酸相关的临床结果

登录后查看更多信息

100 项与叶酸相关的转化医学

登录后查看更多信息

100 项与叶酸相关的专利（医药）

登录后查看更多信息

34,531

项与叶酸相关的文献（医药）

2024-12-01·Journal of psychosomatic obstetrics and gynaecology

Investigating socioeconomic disparities of Kangaroo mother care on preterm infant health outcomes.

Article

作者: Muhammad Muneeb Hassan ; Muhammad Ameeq ; M H Tahir ; Sidra Naz ; Laraib Fatima ; Alpha Kargbo

Several studies have been conducted to examine the complicated relationships between various factors that influence Kangaroo mother care (KMC) for preterm infants. However, the extended socio-economic model has not been seen in any of the previous studies that looked into the factors related to KMC and how it affects the health outcomes of babies born before in our study population. This study examines the various dimensions of KMC implementation and its influence on the health outcomes of premature infants. The current cross-sectional study was carried out in South Punjab, Pakistan, covering both private and public KMC units in obstetrics and gynecology departments. The study included a sample size of 719 patients and was conducted during a period covering 21 September 2022 to 14 October 2023. Multinomial logistic regression analysis is employed to ascertain the factors by using SPSS-26 (SPSS Inc., Chicago, IL). The use of folic acid (OR: 1.44; 95% CI: 0.87-3.11) and factor anemia (OR: 8.82; 95% CI: 1.69-14.59) no significantly correlated with better health outcomes, while environmental toxin exposure had a negative impact (OR: 0.90). The findings underscore the need for comprehensive interventions and policies to bridge socioeconomic gaps, ensuring all preterm infants benefit from KMC.

2024-12-01·The Journal of dermatological treatment

The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review.

Review

作者: Anouk G M Caron ; Manja Bloem ; Hajar El Khattabi ; Ayla C de Waal ; Astrid M van Huizen ; Nerissa P Denswil ; Louise A A Gerbens ; Phyllis I Spuls

Background:Methotrexate is an off-label therapy for atopic dermatitis. A lack of consensus on dosing regimens poses a risk of underdosing and ineffective treatment or overdosing and increased risk of side effects. This systematic review summarizes the available evidence on dosing regimens.Materials and methods:A literature search was conducted, screening all randomized controlled trials (RCTs) and guidelines published up to 6 July 2023, in the MEDLINE, Embase, and Cochrane Library databases.Results:Five RCTs and 21 guidelines were included. RCTs compared methotrexate with other treatments rather than different methotrexate dosing regimens. The start and maintenance doses in RCTs varied between 7.5-15 mg/week and 14.5-25 mg/week, respectively. Despite varied dosing, all RCTs demonstrated efficacy in improving atopic dermatitis signs and symptoms. Guidelines exhibited substantial heterogeneity but predominantly proposed starting doses of 5-15 mg/week for adults and 10-15 mg/m²/week for children. Maintenance doses suggested were 7.5-25 mg/week for adults and 0.2-0.7 mg/kg/week for children. One guideline suggested a test dose and nearly half advised folic acid supplementation.Conclusion:This systematic review highlights the lack of methotrexate dosing guidelines for atopic dermatitis. It identifies commonly recommended and utilized dosing regimens, serving as a valuable resource for clinicians prescribing methotrexate off-label and providing input for an upcoming consensus study.

2024-12-01·Applied microbiology and biotechnology

Role of folic acid in regulating gut microbiota and short-chain fatty acids based on an in vitro fermentation model.

Article

作者: Xiaogu Zheng ; Chenlan Xia ; Manman Liu ; Hongchen Wu ; Jiaqian Yan ; Zihao Zhang ; Yingjie Huang ; Qing Gu ; Ping Li

Folic acid deficiency is common worldwide and is linked to an imbalance in gut microbiota. However, based on model animals used to study the utilization of folic acid by gut microbes, there are challenges of reproducibility and individual differences. In this study, an in vitro fecal slurry culture model of folic acid deficiency was established to investigate the effects of supplementation with 5-methyltetrahydrofolate (MTHF) and non-reduced folic acid (FA) on the modulation of gut microbiota. 16S rRNA sequencing results revealed that both FA (29.7%) and MTHF (27.9%) supplementation significantly reduced the relative abundance of Bacteroidetes compared with control case (34.3%). MTHF supplementation significantly improved the relative abundance of Firmicutes by 4.49%. Notably, compared with the control case, FA and MTHF supplementation promoted an increase in fecal levels of Lactobacillus, Bifidobacterium, and Pediococcus. Short-chain fatty acid (SCFA) analysis showed that folic acid supplementation decreased acetate levels and increased fermentative production of isobutyric acid. The in vitro fecal slurry culture model developed in this study can be utilized as a model of folic acid deficiency in humans to study the gut microbiota and demonstrate that exogenous folic acid affects the composition of the gut microbiota and the level of SCFAs. KEY POINTS: • Establishment of folic acid deficiency in an in vitro culture model. • Folic acid supplementation regulates intestinal microbes and SCFAs. • Connections between microbes and SCFAs after adding folic acid are built.

209

项与叶酸相关的新闻（医药）

2024-04-03

·PRNewswire

Merck Manuals: A Discussion on Dietary Supplements

RAHWAY, N.J., April 3, 2024 /PRNewswire/ -- Three in four Americans use a dietary supplement. Yet despite their prevalence, some experts say greater attention should be paid to when supplements should – and shouldn't – be used. In a new editorial from MerckManuals.com, Laura Shane-McWhorter, PharmD, University of Utah College of Pharmacy, addresses some of the things to consider around dietary supplements. 1. Diet vs. daily pills In many cases, it may be better to adjust your diet and lifestyle rather than take a daily pill, says Shane-McWhorter. A varied and healthy diet may be a better way to obtain nutrients. For example, it's typically better to eat salmon or another healthy fish a few times a week than it is to take a fish oil or omega-3 fatty acid supplement, says Shane-McWhorter. 2. Regulation requirements A common critique of dietary supplements is that they're not regulated. That's not exactly true, says Shane-McWhorter. Dietary supplement makers are required to follow good manufacturing processes and should report adverse effects under the Consumer Protection Act. Still, manufacturers are not required to disclose information on all ingredients to consumers, and the Food & Drug Administration does not analyze products before they're marketed and sold. Bottom line: there is less oversight into what's actually going into a bottle of dietary supplements, when compared with prescription drugs and over-the-counter products. 3. Consider the category In general, certain categories of dietary supplements may be more harmful than others, says Shane-McWhorter. Products including weight loss supplements, anything promoting bodybuilding, or "men's health" (sexual performance aids) can be particularly risky. Still, Shane McWhorter adds other supplements like fish oil, vitamin D, folic acid, and zinc may be useful in certain settings. 4. Always consult an expert Before starting any dietary supplement, it's important to have a conversation with your doctor. Some supplements can interact with the effectiveness and dosing of already-prescribed medications or treatments, among other concerns, says Shane-McWhorter. You can read more of Shane-McWhorter's advice on dietary supplements in this editorial on MerckManuals.com. About The Merck Manuals and MSD Manuals First published in 1899 as a small reference book for physicians and pharmacists, The Merck Manual grew in size and scope to become one of the world's most widely used comprehensive medical resources for professionals and consumers. As The Manual evolved, it continually expanded the reach and depth of its offerings to reflect the mission of providing the best medical information to a wide cross-section of users, including medical professionals and students, veterinarians and veterinary students, and consumers. In 2015, The Manuals kicked off Global Medical Knowledge 2020, a global initiative with the goal to make the best current medical information accessible by up to three billion professionals and patients around the world by 2020. The Manuals achieved that goal, and today its medical information is available in nearly 250 countries and in 14 languages. It's continuing its ambitious mission through outreach, education and creating new reliable medical resources. For access to thousands of medical topics with images, videos and a constantly expanding set of resources, visit MerckManuals.com or MSDManuals.com and connect with us on social media: For Consumers in the U.S. and its territories: X (formerly Twitter) and Facebook. For Professionals in the U.S. and its territories: X (formerly Twitter) and Facebook About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. SOURCE The Merck Manuals

2024-04-01

·美通社

科学合理补充营养，让孕育有"备"而来

厦门 2024年4月1日 /美通社/ -- 3月29日，中华医学会第十五次全国妇产科学术大会在厦门顺利召开。拜耳特邀日本东京杉山医院妇产丸之内院长黑田惠司教授在主会场做《日本生育治疗现状和补充多种维生素的重要性》主题演讲，分享了含叶酸的复合维生素在生殖领域获益的最新临床研究结果，并与国内生殖领域的大咖专家一起参与了亚洲生殖学术论坛，就 "反复流产"、"生育力和营养管理"等焦点话题展开深入地交流与探讨。黑田惠司教授在主题演讲中谈到，日本每年新生人口数量一直在持续下降。1950年日本新生婴儿200多万名，到了2022年，新生儿的数量只有76万名。日本女性初婚及初产年龄持续增高，包括卵巢储备功能下降在内的多种因素，是生育力下降的重要原因。此外，压力、饮食和季节等因素导致营养不良现象增加，也会导致生育能力下降，还会增加孕期并发症的风险，影响胎儿未来健康。包含叶酸、维生素D和其他关键营养素在内的营养摄入对于孕前护理非常重要。日本东京杉山医院妇产丸之内院长黑田惠司教授做主题演讲黑田惠司教授分享的最新研究结果显示：60%的日本不孕女性存在MTHFR（亚甲基四氢叶酸还原酶）突变，但无论属于何种MTHFR基因多态性，补充含有0.8毫克叶酸、维生素B6、B12和维D的复合维生素（爱乐维 ® ）可有效改善叶酸和同型半胱氨酸水平，从而可以极大降低神经管缺陷（NTDs）风险。此外，补充复合维生素还可以改善妊娠结局。其中，维生素D跟流产有密切的联系，如果是缺乏或者不足的话，流产率会增加1.6倍，因此，维生素D在不孕症治疗中常被使用以改善妊娠率。黑田惠司教授强调,目前有研究结果显示，相比于单纯补充维生素D，联合补充复合维生素对于改善临床妊娠率的获益更大。在随后举行的亚洲生殖学术论坛中，针对"反复流产"话题，黑田惠司教授谈到，造成反复性流产实际上有非常多的因素，但是有一半是不明原因的流产，因此在制定治疗方案之前，应该进行多项检查，可考虑宫内环境、维生素D和TH-1、TH-2的细胞比等检测。根据到现在为止的临床经验数据来看，在妊娠前女性应该就开始服用叶酸、VD等营养素的补充，这样可以很好地预防流产，提高活产率。对此，黑田惠司教授进一步表示："日本和中国女性当中都会有60%-70% MTHFR基因突变的比率，我们的建议就是推荐前一个月或者更早就开始进行最佳的复合维生素补充的计划，有助于安全的妊娠和活产。" 目前，《围受孕期增补叶酸预防神经管缺陷指南》建议在女性在孕前至少三个月开始进行叶酸和多种微量营养素的补充。《生殖健康与多种微量营养素补充的中国专家共识》指出，备孕期间通过补充含0.8mg叶酸多种微量营养素有可能增加一年内妊娠率，降低成功妊娠的时间成本。

2024-03-20

·PRNewswire

M8 Pharmaceuticals, an Acino company, signs an exclusive agreement with SERB Pharmaceuticals to bring Voraxaze® (Glucarpidase) to Latin America

PARIS, March 20, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ("M8") and SERB Pharmaceuticals ("SERB"), a global specialty pharmaceutical company, are collaborating to bring an important drug for cancer patients to Latin America. Under the agreement, M8 will register, market and commercialize SERB's supportive oncology product Voraxaze® (glucarpidase) in Latin America Voraxaze® is a carboxypeptidase that reduces toxic plasma methotrexate concentration in adults and children with delayed methotrexate elimination or at risk of methotrexate toxicity. Only Voraxaze® can lower methotrexate (MTX) levels by ≥97% in 15 minutes, reducing the risk for severe toxicities and death.1-3 Voraxaze® is approved in the US, where it has been available since 2012, as well as in Europe and Japan. In the US Voraxaze® is included in the National Comprehensive Cancer Network guidelines. "We are proud to partner with M8, a company that shares our passion for addressing unmet patient needs. Together, we will ensure this critical medicine becomes accessible to patients across Latin America," said Antoine Bernasconi, Executive VP and Chief Commercial Officer for EMEA/International at SERB. "Bringing this important product to Latin America represents an important step in our global expansion and our ambition to help more patients around the world." "We are delighted to start this significant collaboration with SERB. It enables M8 to offer Latin American patients solutions for high medical needs, while leveraging SERB's expertise in treating complex and life-threatening conditions," said Joel Barlan, Head of Latin America at Acino. This strategic partnership aligns with M8's mission to provide the people of Latin America with access to innovative medicines and strengthen its presence within onco-hematology and rare diseases in the region. Through this collaboration a larger number of patients in urgent need will benefit from life-saving treatments in underserved areas. About High Dose Methotrexate Toxicity High Dose Methotrexate (HDMTX) chemotherapy is used to treat or prevent the recurrence of certain types of cancer in adults and children, such as leukemia, lymphoma, and osteosarcoma. Despite standard supportive measures, HDTMX may induce renal dysfunction in some patients, delaying MTX elimination. This may result in sustained elevated levels of MTX concentration, which in turn may cause acute renal toxicity and other systemic adverse reactions that do not respond to standard doses of first-line therapy. Where approved, administering Voraxaze® may quickly lower MTX levels and avoid further systemic damage. It breaks down methotrexate into inactive metabolites, which are then eliminated from the body by routes other than the kidney – primarily the liver. Voraxaze® is the only drug able to reduce toxic plasma methotrexate levels. Voraxaze® is not currently registered in Latin American territories. About SERB Pharmaceuticals SERB is a global specialty pharmaceutical company with a growing portfolio of medicines for emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families. SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. SERB operates in the US as BTG Pharmaceuticals. Learn more at . About M8 Pharmaceuticals, an Acino company M8 is a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and established therapeutics in Latin America. We aim to become the preferred pharmaceutical partner for licensing high-value, innovative, and proven therapies across our main therapeutic areas: CNS, respiratory, cardiometabolic, immunology, gastroenterology, onco-hematology, and rare diseases. Our mission is to provide the people of Latin America with access to the innovative and proven medicines they need to transform their lives. In December 2023, M8 was acquired by Acino, a Swiss pharmaceutical company headquartered in Zurich. About Acino Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi-based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these markets. We leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For further information contact: Chris Sampson, Director, Corporate Communications and ESG [email protected] Larisa Bernstein, Global Head of Communications [email protected] References: 1.Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomes. J Clin Oncol. 2010;28(25):3979-3986. 2.Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-1482. 3. Voraxaze®. Prescribing information. BTG International Inc.; 2019. Voraxaze® US indication and limitations of use Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function. Limitations of Use: Voraxaze® is not recommended in patients who exhibit the expected clearance and plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate. Important safety information Warnings and precautions Serious Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic reactions, may occur. Serious hypersensitivity reactions occurred in less than 1% of patients Monitoring Methotrexate Concentration/Interference with Assay Methotrexate concentrations within 48 hours following Voraxaze® administration can only be reliably measured by a chromatographic method due to metabolite interference. Measurement of methotrexate concentrations within 48 hours of Voraxaze® administration using immunoassays results in an overestimation of the methotrexate concentration. Adverse reactions In clinical trials, the most common related adverse events (occurring in >1% of patients) were paresthesia, flushing, nausea and/or vomiting, hypotension, and headache. Drug interactions Voraxaze® can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended, and may also reduce the concentrations of other folate analogs or folate analog metabolic inhibitors. Please see the full Prescribing Information. Contact: Gabriela Arellano Telephone: (+52) 1 5544423498 Email: gabriela.arellano@moksha8.com Logo - SOURCE M8 Pharmaceuticals

上市批准并购引进/卖出

100 项与叶酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00070	叶酸	V04CX02 B03BB01	DB00158

研发状态

适应症	最高研发状态	国家/地区	公司
叶酸缺乏	批准上市	中国更多	天津力生制药股份有限公司更多
巨幼红细胞性贫血	批准上市	中国更多	天津力生制药股份有限公司更多
主动脉瓣钙化	临床2期	-	武汉协和医院更多
同型半胱氨酸血症	临床申请批准	中国更多	北京斯利安药业有限公司更多
神经管缺陷	撤市	美国更多	Wyeth Pharmaceuticals LLC 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Alienor study (ARVO2023)	N/A	vitamins A \| vitamin D \| vitamin E ... 更多	963	Vitamin E	(衊簾簾窪製糧製衊繭觸) = 遞壓憲繭淵繭鑰糧鏇鏇餘餘鹽築艱築選廠憲簾 (範繭獵築積構顧鏇鑰鹽, 0.02 ~ 0.28)	积极	2023-04-23
				Vitamin B9	(衊簾簾窪製糧製衊繭觸) = 鹹艱繭醖築蓋鏇憲蓋積餘餘鹽築艱築選廠憲簾 (範繭獵築積構顧鏇鑰鹽, 0.01 ~ 0.23)
ISRCTN67978523 (Pubmed \| J Nutr)	N/A	高血压	-	high-nitrate beetroot juice and folic acid	(鏇壓範齋築壓鏇獵餘積) = 襯願鹹範餘鏇壓鹽簾襯繭蓋醖襯壓獵齋繭壓築 (簾積顧齋製襯願鬱壓淵 ) 更多	-	2020-07-30
				high-nitrate beetroot juice and placebo	(鏇壓範齋築壓鏇獵餘積) = 獵獵憲獵製廠觸糧鹽製繭蓋醖襯壓獵齋繭壓築 (簾積顧齋製襯願鬱壓淵 ) 更多
EULAR2022	N/A	新型冠状病毒感染	-	Folic acid only	-	-	2022-06-01
				Methotrexate and folic acid
NCT03172325 (Pubmed \| J Rheumatol) 人工标引	临床3期	类风湿关节炎	136	methotrexate+folic acid+prednisolone+CinnoRA®	- 更多	非劣	2017-07-20
				methotrexate+folic acid+prednisolone+Humira
NCT01134341 (Pubmed \| Clin Cancer Res) 人工标引	临床1/2期	皮肤T细胞淋巴瘤	34	Bexarotene+B12+Folic Acid+levothyroxine+atorvastatin+Pralatrexate	(簾遞構網廠遞製鹹廠鏇) = 醖願範糧範築網鹹鏇築積獵鏇艱繭憲選艱鹽遞 (簾壓糧簾齋選鏇憲淵衊 ) 更多	积极	2017-07-15
NCT00794885 (CSPPT, Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床4期	脑卒中 \| 高血压	20,702	folic acid+enalapril	憲窪膚構觸鑰衊糧淵艱(製壓窪鹽繭選廠糧鹽觸) = 艱鹽齋襯憲糧鹹築遞鏇鹽窪窪齋簾積選衊齋淵 (鑰鹹鬱衊糧範築遞鹹窪 ) 更多	积极	2015-04-07
				enalapril	憲窪膚構觸鑰衊糧淵艱(製壓窪鹽繭選廠糧鹽觸) = 築憲鹹網願憲鹽構積選鹽窪窪齋簾積選衊齋淵 (鑰鹹鬱衊糧範築遞鹹窪 ) 更多
ChiCTR-SOC-17010976 (Pubmed)	N/A	先天性畸形	-	Women taking recommended dosage of FA	艱築製膚醖衊襯願窪鹽(淵鑰醖醖膚築積鹽廠窪) = 鏇淵製網艱選鏇壓選餘醖積範積積廠艱築鏇鹹 (糧範鹽鬱糧觸範築蓋鬱 )	-	2023-08-07
				folic acid (Women without supplementation)	艱築製膚醖衊襯願窪鹽(淵鑰醖醖膚築積鹽廠窪) = 鏇積築廠鹹窪網憲顧憲醖積範積積廠艱築鏇鹹 (糧範鹽鬱糧觸範築蓋鬱 )
ASH2023	N/A	镰状细胞血症	32	Hydroxyurea and folic acid	鬱鑰糧選廠鑰築淵遞醖(鏇範憲衊範壓壓襯淵鹽) = 簾廠憲艱廠築鏇範夢網窪簾鹽艱積願鑰簾夢餘 (願餘繭製艱獵窪顧淵積 )	-	2023-12-10
NCT02437721 (Pubmed)	N/A	-	360	5,10-methylenetetrahydrofolate reductase (Breastfed infants)	鹹願窪積廠顧構網願廠(積願壓窪構蓋鹽鏇製製) = 蓋襯鏇廠齋獵壓築繭膚壓醖顧窪醖鏇鹹醖範壓 (構糧餘鏇餘構夢觸鏇齋 )	-	2023-03-01
				Infant formula with folic acid	鹹願窪積廠顧構網願廠(積願壓窪構蓋鹽鏇製製) = 憲遞蓋鬱繭廠夢衊鏇憲壓醖顧窪醖鏇鹹醖範壓 (構糧餘鏇餘構夢觸鏇齋 )
Alienor Study (ARVO2022)	N/A	年龄相关性黄斑变性	963	Vitamin B5	網壓範遞蓋蓋齋觸壓網(淵築積窪鏇鏇蓋簾遞製) = 醖築簾夢糧衊遞鑰蓋壓選選廠壓醖簾夢網壓網 (壓壓選鏇繭鬱製獵膚窪, 1.84mg)	-	2022-05-01
				Vitamin B6	網壓範遞蓋蓋齋觸壓網(淵築積窪鏇鏇蓋簾遞製) = 網鑰觸範窪衊淵廠構鑰選選廠壓醖簾夢網壓網 (壓壓選鏇繭鬱製獵膚窪, 0.60mg)